RxDoctor Payments Data

Amber Lindholm

Psychiatric/Mental Health · Iron Mountain, MINPI 1225383672

Payments from drug & device makers

$762in general payments, 2019–2025

Across 34 payments — averaging $22.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alkermes, Inc.$460
  • Teva Pharmaceuticals USA, Inc.$125
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$94
  • E.r. Squibb & Sons, L.L.C.$43
  • Supernus Pharmaceuticals, Inc.$24
  • AbbVie$15

What the payments were for

  • Food & beverage$52969%
  • Education$23331%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$762 in reported general payments places this provider in the 55th percentile of 638 psychiatric/mental health providers in Michigan.

See all psychiatric/mental health providers in Michigan

Medicare billing

Part B allowed, 2024
$8,457
Medicare patients
43
Services billed
194

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate86$279,832
CaplytaLumateperone Tosylate151$247,298
Invega TrinzaPaliperidone Palmitate28$207,704
LybalviOlanzapine/Samidorphan Malate93$151,580
AristadaAripiprazole Lauroxil54$149,939
VraylarCariprazine Hcl106$145,363
Abilify MaintenaAripiprazole38$104,382
RexultiBrexpiprazole61$87,012
TrintellixVortioxetine Hydrobromide161$80,396
Risperdal ConstaRisperidone Microspheres14$33,918
LatudaLurasidone Hcl25$27,419
Lurasidone Hcl156$25,154
ValiumDiazepam14$14,281
Quetiapine Fumarate382$8,022
Clozapine315$7,985

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Alkermes, Inc.Lybalvi, Aristada$460$301,520147 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$94$247,298151 claims
AbbVieVraylar, Viibryd$15$149,823118 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 638 psychiatric/mental health providers in Michigan.

Other psychiatric/mental health in Iron Mountain

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →